公开(公告)号：US20210155710A1

公开(公告)日：2021-05-27

申请号：US16972298

申请日：2019-06-05

Applicant: Amgen Inc.

Inventor： Scott KUHNS ,  Junyan SHU ,  Qingchun ZHANG

IPC: C07K16/32 ,  C07K16/28

Abstract: Provided herein are methods of modulating Antibody Dependent Cellular Phagocytosis (ADCP) activity of an antibody composition. In exemplary embodiments, the method comprises modulating the amount of (a) galactosylated glycans of the antibody, (b) afucosylated glycans of the antibody, (c) high mannose glycans of the antibody, or (d) a combination thereof, to modulate ADCP activity of the antibody, as further described herein.

公开(公告)号：US20240417442A1

公开(公告)日：2024-12-19

申请号：US18798878

申请日：2024-08-09

Applicant: Amgen Inc.

Inventor： Quanzhou LUO ,  Scott KUHNS ,  Diana WOEHLE ,  Matthew JERUMS ,  XueJun HAN ,  Kelli M.G. MATTHIES

IPC: C07K14/71 ,  C07K1/16

Abstract: The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.

公开(公告)号：US20220033511A1

公开(公告)日：2022-02-03

申请号：US17275140

申请日：2019-09-10

Applicant: Amgen Inc.

Inventor： Alla POLOZOVA ,  Qingchun ZHANG ,  Scott KUHNS ,  Dong XIANG

IPC: C07K16/28 ,  C07K16/32 ,  C07K16/24

Abstract: The present disclosure provides a method of controlling the Antibody Dependent Cellular Cytotoxicity (ADCC) activity of a glycosylated and afucosylated IgG1 antibody composition. In exemplary embodiments, the method includes (1) determining the ADCC activity of a glycosylated and afucosylated IgG1 antibody composition; and (2) increasing or decreasing the ADCC activity of the IgG1 antibody composition by increasing or decreasing the amount of terminal β-galactose in the afucosylated glycan species at the consensus glycosylation site. Related methods of matching ADCC activity of a reference glycosylated and afucosylated IgG1 antibody composition and methods of engineering a specific target ADCC activity of a glycosylated and afucosylated IgG1 antibody composition are further provided herein.

公开(公告)号：US20160025749A1

公开(公告)日：2016-01-28

申请号：US14774668

申请日：2014-03-07

Applicant: AMGEN INC.

Inventor： Sungae PARK ,  Scott KUHNS ,  Jennifer RATTAN ,  Joseph PHILLIPS

IPC: G01N33/74

CPC classification number: G01N33/746 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/1816 ,  A61K39/39591 ,  A61K47/02 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/505 ,  C07K16/22 ,  G01N2333/505

Abstract: The present disclosure provides stable, solid protein formulations. The present disclosure also provides methods of using these formulations in protein detection kits that are stable over a variety of temperatures for extended time periods.

Abstract translation: 本公开提供稳定的固体蛋白质制剂。 本公开还提供了在蛋白质检测试剂盒中使用这些制剂的方法，其在多种温度下可延长时间段是稳定的。

公开(公告)号：US20250076309A1

公开(公告)日：2025-03-06

申请号：US18698098

申请日：2022-10-04

Applicant: AMGEN INC.

Inventor： Palanisamy KANAKARAJ ,  Katariina HUTTERER ,  Scott KUHNS

IPC: G01N33/68 ,  C07K16/18

Abstract: Provided herein are methods of determining product quality of an antibody composition, wherein the product quality is based on the Fcγ receptor II (FcγRI) binding level of the antibody composition. In exemplary embodiments, the method comprises (a) determining the afucosylated glycan content and/or β-galactosylated glycan content of a sample of the antibody composition; (b) optionally, calculating a predicted FcγRII binding level based on the afucosylated glycan content and/or β-galactosylated glycan content as determined in (a); and (c) determining the product quality of the antibody composition as acceptable when (i) the afucosylated glycan content and/or β-galactosylated glycan content is within a target range and/or (ii) the predicted FcγRII binding level is within a target range. Related methods of monitoring product quality and methods of producing an antibody composition are further provided herein.

公开(公告)号：US20220098279A1

公开(公告)日：2022-03-31

申请号：US17426886

申请日：2020-01-29

Applicant: Amgen Inc.

Inventor： Quanzhou LUO ,  Scott KUHNS ,  Diana WOEHLE ,  Matthew JERUMS ,  XueJun HAN ,  Kelli M.G. MATTHIES

IPC: C07K14/71 ,  C07K1/16

Abstract: The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.